Active start on export of Celltrion’s antibody biosimilar Remsima to U.S.
A Celltrion’s affiliate, Celltrion Healthcare announced it will begin to export Remsima(U.S. product name: Inflectra) from its release data on November.
Through its joint news release on the 18th of October, Celltrion Healthcare and Pfizer announced the Remsima’s U.S. release date on November, a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
